Background: Vonoprazan is a novel gastric acid suppressant that is applied in Japan
| INTRODUC TI ON
Helicobacter pylori (H. pylori) infection causes a number of diseases, including chronic atrophic gastritis, peptic ulcer, gastric cancer, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. [1] [2] [3] [4] Nearly half of the world's population is reported to be infected with H. pylori. 5 The incidence of gastric cancer is generally correlated with the prevalence of H. pylori infection, and a higher incidence of gastric cancer is found in East Asian countries as compared to elsewhere. 4 Helicobacter pylori eradication is recommended for the treatment of peptic ulcer and MALT lymphoma. 6 In addition, H. pylori eradication may reduce the risk of gastric cancer. 7 Helicobacter pylori enters its growth phase at intragastric pH levels above 5, and during this growth phase, it is susceptible to antibiotics such as amoxicillin and clarithromycin. 8 The most widely prescribed first-line H. pylori eradication regimen therefore is triple therapy using a conventional proton-pump inhibitor (PPI), amoxicillin, and either clarithromycin or metronidazole, with recommended treatment periods varying by guideline. [9] [10] [11] [12] Recently, however, H. pylori eradication rates have decreased due to increasing prevalence of antibiotic-resistant H. pylori. 13 Alternative eradication therapies, including modifications of the antibiotic combinations, and increasing the dosage and frequency of conventional PPIs, have been attempted to counter this declining eradication success, 14, 15 but reliably potent inhibition of gastric acid secretion and further examination of antibiotic resistance patterns and mechanisms are crucial for maintaining any advantage gained.
Vonoprazan, a new potassium-competitive acid blocker (P-CAB) that strongly inhibits H + /K + ATPase-mediated gastric acid secretion is now being used in Japan, 16 where it has been approved for first-line and second-line H. pylori eradication therapy. 17 Nonrandomized controlled trails and randomized controlled trials have been conducted to evaluate the efficacy of vonoprazan for H. pylori eradication, [17] [18] [19] [20] and meta-analyses of these studies show superior efficacy of vonoprazan-based H. pylori eradication regimens as compared to conventional PPIbased triple therapy regimens. 21, 22 As clarithromycin resistance significantly affects the efficacy of eradication therapy, 17, 23 clarithromycin resistance is a potential confounding factor in these studies, especially in the retrospective analyses. However, in Jung's meta-analysis, 21 there was no subgroup study based on clarithromycin resistance. While in Dong's meta-analysis, 22 even though authors did subgroup analyses based on clarithromycin resistance, the majority of included studies were retrospective. Thus, we conducted a systematic review with meta-analyses using data supplements from the most recently 
| ME THODS

| Literature search strategy
PubMed (Medline), EMBASE, Web of Science and Cochrane Library databases (up to January 5, 2018) were searched using the following keywords: ("vonoprazan", "VPZ", "potassium-competitive acid blocker", "P-CAB", "takecab", "TAK438" or "TAK-438") AND ("Helicobacter pylori eradication", "Helicobacter pylori eradicated", "H. pylori eradication", "H. pylori eradicated", "HP eradication" or "HP eradicated") and MeSH/ Emtree terms as well. The results were limited to human studies but were not restricted by language. To identify additional studies, related references to the articles were screened. Study references were collected in Endnote version 5 (Thomson Reuters, New York, NY, USA).
This review was conducted according to the recommendations from the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement (Table S1 ). 24 The PROSPERO registration number is 42018086947. 25 
| Study selection
Potentially relevant studies were retrieved, and selection criteria ap- Eligible studies were reviewed and data were extracted and recorded in duplicate, independently by the 2 investigators. Disagreements between these 2 investigators were discussed with other investigators, until consensus was achieved.
| Study quality assessment
Methodological quality of included RCTs was assessed using the following items as prescribed by the Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0) 26 : (1) how the random sequence was generated; (2) how patient allocation was concealed; (3) blinding of the patients and researchers; (4) blinding of outcome assessment; (5) is there incomplete outcome data; (6) is there selective outcome reporting; and (7) other potential biases. Nonrandomized studies were assessed in accordance with the Newcastle-Ottawa scale (NOS). 27 NRCTs were assessed by: selection, comparability of study groups, and ascertainment of exposure or outcome.
| Data extraction
Two reviewers independently extracted data from each study using a data extraction form that was designed in advance. The following information was extracted: first author, year of publication, study design, study period, eradication regimens (dosage of vonoprazan or PPI, dosage of antibiotics), treatment period, confirmatory test of eradication, eradication rate (intention-to-treat
[ITT]).
| Statistical analysis
Meta-analysis was performed using STATA 14.1 (Stata Corp LLC, Texas, USA) with random-effects model. Pooled odds ratios (ORs)
were presented as standard plots with 95% confidence intervals (CIs). All P-values were 2-tailed, and P < .05 was considered statistically significant (except for tests of heterogeneity). Statistical heterogeneity was evaluated by the Cochran-Mantel-Haenszel chisquare test and defined at P < .10 and by I-squared statistics. The random-effects model was applied in all analyses. Because the total number of included studies was <10, tests for evaluating publication bias could not be performed.
| RE SULTS
| Study selection and characteristics of included studies
A flow diagram of study identification, inclusion, and exclusion is provided in Figure 1 . Characteristics of the 5 studies are summarized in Table 1 were from the RCTs. All 5 studies provided eradication rates based on clarithromycin susceptibility. However, 2 studies provided data for clarithromycin-susceptible strains. 20, 28 In all 5 studies, the conventional PPI-based triple regimen consisted of a standard dose of PPI (omeprazole, 20 mg; lansoprazole, 30 mg; rabeprazole, 10 mg; esomeprazole, 20 mg), 750 mg of amoxicillin, and either 200 mg or 400 mg of clarithromycin twice per day for 7 days. Two RCTs were conducted with lansoprazole, rabeprazole, and esomeprazole; one NRCT included omeprazole-based data. 20 In the vonoprazan-based therapy, 20 mg of vonoprazan was used instead of conventional PPI. Eradication was confirmed with 13 C-urea breath test 4-8 weeks after conclusion of treatment.
| Risk of bias
The 2 RCTs demonstrated low risk of bias according to the Cochrane reviewer's handbook. The Newcastle-Ottawa Scale scores of the 3
NRCTs ranged from 7 to 9, indicating mild risks of bias. Both RCTs were considered to be of good quality, and all 3 NRCTs achieved high quality.
| Efficacy of vonoprazan-based therapy in different subgroups
The single RCT that provided enough information 17 AMX, amoxicillin; CAM, clarithromycin; CAM-R, clarithromycin-resistant strains; CAM-S, clarithromycin-susceptible strains; ESO, esomeprazole; LPZ, lansoprazole; OPZ, omeprazole; PCS, prospective cohort study; PPI, proton-pump inhibitor; RCS, retrospective cohort study; RCT, randomized controlled trial; RPZ, rabeprazole; UBT, 13 C-urea breath test; VPZ, vonoprazan.
| D ISCUSS I ON
57% in Thailand, and 39% in Japan. 29 Reported prevalence of clarithromycin resistance range from 18% and 19%, respectively, in
Bangladesh and Japan to 26% and 34%, respectively, in China and
Vietnam. 30 Thus the counties or regions with higher H. pylori infection rates also tend to have higher clarithromycin resistance rates.
As stated in the 2 RCTs included in our analysis, either vonoprazanbased or PPI-based therapy can achieve high eradication rates in patients with clarithromycin-susceptible strains, while in patients with clarithromycin-resistant strains both therapies achieved lower eradication rates. 17, 28 These data emphasize the importance of antibiotic resistance to the failure of eradication therapy. Among patients with clarithromycin-resistant H. pylori strains, however, vonoprazan-based regimens appeared superior for patients with clarithromycin-resistant H. pylori strains, and 80% of patients could be cured without clarithromycin. Inaba et al 31 reported an eradication rate of 70% with vonoprazan in patients with failure of first-line conventional PPI triple therapy. In
Murakami's study, 17 a promising eradication rate of 98.0% was achieved with vonoprazan, amoxicillin, and metronidazole triple therapy even after failure of first-line PPI-based therapy with clarithromycin.
The standard dose of 20 mg vonoprazan once daily is approximately equal to 70 mg of omeprazole twice daily in terms of maintaining the intragastric pH levels above 4 (about 85%). 32 Maintaining an intragastric pH above 6 leads to a high H. pylori eradication rate, because increasing the pH to 6 or 7 allows the bacteria to enter the replicative state where they become susceptible to amoxicillin. 10 which is not recommended in most of the current consensus; (3) because relevant RCTs are not abundant, our analysis included less RCT data than ideal; and (4) little data was available on children, so our findings may not be generalizable to children. 43 In conclusion, the efficacy of vonoprazan-based triple therapy for the eradication of clarithromycin-susceptible H. pylori strains is similar to that of conventional PPI-based therapy. Vonoprazanbased therapy is superior to conventional PPI-based therapy for the eradication of clarithromycin-resistant H. pylori strains. However, because the combination of vonoprazan and amoxicillin cure approximately 80% of infections without clarithromycin, the use of vonoprazan in triple therapy results in at least 80% receiving clarithromycin that had not benefit and was thus misused.
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